Achieve Life Sciences, Inc.
ACHV
ACHV: Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.
moreShow ACHV Financials
Recent trades of ACHV by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ACHV's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof Aug. 10, 2021
-
Patent Title: Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof Aug. 10, 2021
Federal grants, loans, and purchases
Followers on ACHV's company Twitter account
Number of mentions of ACHV in WallStreetBets Daily Discussion
Recent insights relating to ACHV
Recent picks made for ACHV stock on CNBC
ETFs with the largest estimated holdings in ACHV
Flights by private jets registered to ACHV